Research programme: dengue NS3 protein inhbitors - Janssen/Medivir
Latest Information Update: 16 Jul 2016
At a glance
- Originator Janssen Pharmaceutica; Medivir AB
- Mechanism of Action Viral nonstructural protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Dengue
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Dengue in USA
- 14 Feb 2011 Early research in Dengue in USA (unspecified route)